Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Temsirolimus + IFN‐α showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with IFN‐α (targeted agent + classic immunotherapy versus classic… (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Temsirolimus + bevacizumab showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (moderate certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether everolimus + bevacizumab changes overall survival (absolute effect size estimates based on survival… compared with IFN α‐2a + bevacizumab (targeted agent + targeted agent versus… (very low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
Sunitinib leads to higher overall survival (absolute effect size estimates based on survival… compared with nivolumab + ipilimumab (targeted agent versus combinations of… (high certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Temsirolimus probably leads to lower overall survival survival (absolute effect size estimates based on… compared with IFN‐α (targeted agent versus classic immunotherapy) (moderate certainty).
1 finding from 1 review
Overall survival: Median length of · people with metastatic breast cancer
Capecitabine‐containing regimens showed no clear difference in overall survival (OS)median compared with chemotherapy regimens without capecitabine (high certainty).
1 finding from 1 review
Overall survival: Median length of · patients with early breast cancer
Capecitabine‐containing regimens probably leads to lower overall survival (OS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
Overall survival (OS) · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to lower overall survival (OS) compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Overall survival ‐ not reported · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Median overall survival · people with malignant pleural mesothelioma
1 finding from 1 review
Intervention not reported
Median overall survival · people with malignant pleural mesothelioma
1 finding from 1 review
Overall survival (Death) · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines showed no clear difference in overall survival (Death) compared with single agent IRI (low certainty).
1 finding from 1 review
Intervention not reported
Overall 5‐year survival1 · women with stage I/II epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
1008 participants
High
Intervention not reported
Overall Survival (median · Patients with brain metastases
The intervention showed no clear difference in overall Survival (median (low certainty).
1 finding from 1 review
Overall survival ‐ first‐line studies · women with advanced or recurrent endometrial cancer
mTOR inhibitors showed no clear difference in overall survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).
1 finding from 1 review
Overall survival (number of deaths at · Patients with treating MF
Ruxolitinib showed no clear difference in overall survival (number of deaths at compared with best available therapy (low certainty).
1 finding from 1 review
Overall survival Censored · participants with unresectable hepatocellular carcinoma
It is very uncertain whether recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) changes overall survival Censored compared with hydroxycamptothecin (very low certainty).
1 finding from 1 review
Intervention not reported
Overall 10‐year3 survival · women with stage I/II epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
925 participants
High
Overall survival: second/third‐line trials ( · women with advanced or recurrent endometrial cancer
mTOR inhibitors showed no clear difference in overall survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (low certainty).
1 finding from 1 review
Survival (overall and event‐free) ‐ not reported · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found